



ASX release

6 March 2018

Resignation of CFO/Company Secretary

AtCor Medical (ASX: ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced that Peter Manley, CFO and Company Secretary, will be leaving AtCor at the end of March. Peter has provided 13 years of dedicated service to AtCor including leading the company through its IPO in 2005.

The Company Secretarial responsibilities will be assumed immediately by Jarrod White of Traverse Accountants who will also become CFO after a transition during the month of March.

Jarrod is a Partner/Director at Traverse Accountants in Sydney and has significant experience in listed company compliance, finance, and accounts management.

AtCor's CEO, Craig Cooper, said: "I and other Directors would like to thank Peter for his time with us and wish him well for the future. We also welcome Jarrod as AtCor pursues new opportunities to underwrite future growth."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of arterial stiffness, target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe.

For further information, please contact:

Craig Cooper - CEO
+61 (2) 9874 8761